Inclusion Criteria:

• Minimum of nineteen (19) years of age.
• Diagnosed with bilateral ocular hypertension or primary open angle glaucoma for at least six months prior to screen visit.
• IOP of 20-35 mmHg in both eyes and not more than 5 mmHg difference between eyes at the Baseline 0800 ±1 hour IOP measurement.
• Willing and able to provide informed consent.
• Able to adhere to treatment/visit plan.

Exclusion Criteria:

Systemic Conditions:

• History of severe, unstable or uncontrolled cardiovascular, hepatic or renal disease.
• History of bronchial asthma or chronic obstructive pulmonary disease.
• Allergies to sulfa drugs.

Ocular Conditions:

• Chronic or recurrent severe ocular inflammatory disease.
• Ocular infection or inflammation within three (3) months of the study visit.
• Subjects currently treated with more than two ocular hypotensive medications.
• Subjects having previous exposure to: adrenergic antagonists, topical prostaglandin analogues (including latanoprost, unoprostone, travoprost and bimatoprost) within four (4) weeks of the baseline visit; adrenergic agonists within two (2) weeks of the baseline visit; and cholinergic agonists and carbonic anhydrase inhibitors within five (5) days of the baseline visit.
• History of any severe ocular pathology that would preclude the administration of a topical prostaglandin or beta-blocker.
• History of severe or serious hypersensitivity to topical or systemic prostaglandins or beta-blockers.
• Intraocular pressures less than 20 mmHg when off all ocular medications.
• Cornea thickness greater than 600 microns.

Women:

• Women of childbearing potential who are sexually active, or plan to become sexually active, and don't have a vasectomized partner, must agree to use at least one of the following acceptable contraceptive methods: condoms (male or female with or without a spermicidal agent, a diaphragm or cervical cap with spermicide, an intrauterine device (IUD) or hormonal-based contraception. Women of childbearing potential are defined as women who are not surgically sterile or not postmenopausal (at least 12 months without menstrual period).
• Nursing mothers.
• Pregnancy
• General
• Subjects less than nineteen (19) years of age.
• Therapy with another investigational agent within 30 days of Screening Visit.